PHILADELPHIA--(BUSINESS WIRE)--Chimeron Bio, an RNA company pioneering a novel class of mRNA-based vaccines and therapeutics, is pleased to announce the appointment of Dr. Juan José Daboub and Dr. Wilmot James to its Accessible Medicines Advisory Board (AMAB). AMAB is established to develop and execute strategies to make Chimeron Bio’s self-amplifying mRNA platform and any medicines developed by Chimeron Bio accessible to countries and its citizens worldwide. The role of this board is to work closely with private and public bodies for capability building and provide nations the opportunity to access state of the art vaccines and therapeutics.
Dr. Juan José Daboub is a former Minister for Finance, Chief of Staff to the President of El Salvador, and Managing Director of the World Bank. Currently, Dr. Daboub is the chairman and CEO of The Daboub Partnership and Founding Chief Executive Officer of the Global Adaptation Institute. He has taught at premier institutions including Princeton University and is a member of several boards of directors that span across industry segments. He is the co-chair of The World Economic Forum Global Agenda Council on Climate Change, and an Advisory Panel member of the UNFCCC Momentum for Change initiative.
Dr. Wilmot James is a former Shadow Minister for Health, South Africa, and currently a Senior Research Scholar at the Institute for Social and Economic Research and Policy at Columbia University in New York City. At Columbia University, he teaches a course on catastrophic risks and conducts research in the areas of biosecurity, catastrophes and vulnerable populations, particularly children, with a focus on Africa. He is also a senior consultant to the Washington DC-based Nuclear Threat Initiative (NTI) on biosecurity. Dr. James will convene the Schmidt-Futures Vaccine Safety and Confidence-Building Working Group based at Columbia University in New York City and the University of the Witwatersrand in Johannesburg.
“I am honored to have Dr. Daboub and Dr. James as part of Chimeron Bio’s AMAB,” said Mr. Sven Otto Littorin, the Chair of the AMAB. “With decades of experience in policy making and working in challenging situations, I have no doubt that they will have a huge impact towards Chimeron’s bold initiative,” said Mr. Littorin.
“Equal access to the best medicines is a goal we all should strive for. At Chimeron Bio, scientists are developing solutions to illnesses that will save lives and improve livelihoods, including vaccines for cancer and COVID-19. On COVID-19, Chimeron Bio is developing a vaccine with a goal to make it more accessible to people in developing nations, simpler to handle, less expensive and more reliable than what is in the market today,” said Dr. Juan José Daboub.
“The response to COVID-19 has shown how vitally important it is to take every reasonable action possible to make vaccines and therapies accessible to communities to fight epidemics and pandemics. It is my privilege to assist a pioneering company like Chimeron Bio in its efforts to lower barriers to vaccine and therapeutics access, so meaningfully captured in the name of the entity - Accessible Medicines Advisory Board - whose mission I would serve,” said Dr. Wilmot James.
“At Chimeron Bio, our scientists are working hard to develop sustainable, safe, effective, and easy to deploy RNA vaccines for COVID-19 and other infectious diseases, all geared to have a true impact on lives and livelihoods worldwide. Towards this remarkable core mission, I am very pleased to welcome Drs. Daboub and James to our AMAB team,” said Dr. Jolly Mazumdar, CEO of the Company.
About Chimeron Bio
Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA drugs and vaccines for various diseases. The company is using its proprietary ChaESARTM platform to develop a pipeline in oncology, rare genetic disorders, and infectious diseases. It is developing two COVID-19 vaccine candidates each with its unique mechanism of action. The candidates have shown strong promise in early safety assessment and are under further development. For more information, visit www.chimeron.com.
